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Abstract
Background: Although stavudine (D4T) remains frequently used in low-income countries in Asia, associated long-term
toxicity data are scarce. The aim of this study was to determine the long-term incidence of severe D4T-toxicity (requiring
drug substitution) and associated risk factors in HIV-infected Cambodians up to six years on antiretroviral treatment (ART).
Methodology/Principal Findings: This is a retrospective analysis of an observational cohort, using data from an ART
program with systematic monitoring for D4T-toxicity. Probabilities of time to D4T substitution due to suspected D4T toxicity
(treatment-limiting D4T toxicity) were calculated, a risk factor analysis was performed using multivariate Cox regression
modelling. Out of 2581 adults initiating a D4T-containing regimen, D4T was replaced in 276 (10.7%) patients for neuropathy,
14 (0.5%) for lactic acidosis and 957 (37.1%) for lipoatrophy. The main early side effect was peripheral neuropathy (7.0% by 1
year). After the first year, lipoatrophy became predominant, with a cumulative incidence of 56.1% and 72.4% by 3 and 6
years respectively. Older age (aHR 1.8; 95%CI: 1.4–2.3) and lower baseline haemoglobin (aHR 1.7; 95%CI: 1.4–2.2) were
associated with the occurrence of neuropathy. Being female (aHR 3.8; 95%CI: 1.1–12.5), a higher baseline BMI (aHR 12.6;
95%CI: 3.7–43.1), and TB treatment at ART initiation (aHR 8.6; 95%CI: 2.7–27.5) increased the likelihood of lactic acidosis.
Lipoatrophy was positively associated with female gender (aHR 2.3; 95%CI: 2.0–2.6), an older age (aHR 1.3; 95%CI: 1.1–1.4),
and a CD4 count ,200 cells/mL (aHR 1.3; 95%CI: 1.1–1.5).
Conclusions: Stavudine-based treatment regimens in low-income countries are associated with significant long-term
toxicities, predominantly lipoatrophy. Close clinical monitoring for toxicity with timely D4T substitution is recommended.
Phasing-out of stavudine should be implemented, as costs allows.
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Introduction
HIV is one of the major health problems in low and middle
income countries (LMIC), with over 30 million of people infected.
Over the last several years, a successful scaling-up of antiretroviral
treatment (ART) has occurred, with currently over five million
individuals on treatment. Of these, around 14% live in Asia [1].
The availability of a cheap, generic fixed-dose combination (FDC)
has been a key issue in achieving this [2]. In line with WHO
recommendations at the start of the ART role-out, almost all
national programs have implemented first line treatment consist-
ing of a FDC containing stavudine (D4T), lamivudine and
nevirapine [3].
Given increasing reports of D4T-related toxicity, including
neuropathy, lactic acidosis and lipoatrophy, WHO 2006 guide-
lines have recommended to use alternative drugs in stead of D4T
[4]. Besides the adoption of an alternative first line regimen for
those initiating ART, phasing-out of D4T would additionally
require the replacement of D4T for the millions of patients
currently using this drug. The recommendation to phase-out D4T
was reinforced in the 2010 guidelines [5]. However, recent data
demonstrate that the vast majority of individuals in LMIC still take
D4T-containing regimens [1]. For a number of reasons, including
cost and the operational challenges of the complete phasing-out of
D4T, frequent use of D4T-containing regimens will most likely
remain the reality on the field for the next years to come. In
Cambodia, for instance, the use of D4T-based first line treatment
continues up to this day.
Despite the ongoing use of D4T, its recognized potential of
toxicity and the maturing of many ART programs [6–9], only
scarce data on the incidence and timing of its long-term toxicity
beyond the first few years on ART are available, particularly from
Asian countries. Moreover, studies exploring risk factors of D4T-
related toxicity in this region are surprisingly limited. Conse-
quently, it remains unclear which groups might benefit most from
any targeted intervention or should be prioritized for phasing-out
of D4T. Given the paucity of available data in South-East Asia,
including Cambodia, the aim of this study was to determine the
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30647long-term incidence of severe D4T-toxicity and associated risk
factors in HIV-infected Cambodians. Using data from an ART
cohort with systematic monitoring for D4T-toxicity performed
from the program-onset in 2003, we provide data on the long-term
toxicity associated with D4T by up to six years of treatment.
Methods
Study design and study population
We conducted a retrospective cohort study between March
2003 and December 2010 at the Sihanouk-Hospital-Center-of-
Hope (SHCH) in Phnom Penh, Cambodia. Since March 2003,
this tertiary care hospital provides comprehensive HIV care at no
cost, as part of the national ART program. All adult, ART-naive
HIV-infected patients having initiating D4T-based ART at
SHCH were included.
Antiretroviral treatment initiation and monitoring
Treatment initiation on ART was according to WHO
recommendations: all patients with WHO stage IV, WHO stage
III with CD4 cell count ,350 cells/mL or with CD4 cell count
,200 cells/mL were eligible for ART. First line treatment
consisted of a generic FDC containing D4T, lamivudine and
nevirapine. Zidovudine or efavirenz was prescribed in case of
contraindications to D4T or nevirapine. From 2006 on, D4T was
prescribed as 30 mg bid, irrespective of body weight. Prior to that,
dosing was done according to body weight with a higher dose
(40 mg bid) for individuals with a body weight above 60 kg [4].
Before ART initiation, extensive patient counselling was done,
including on the occurrence of toxicities. Patients were seen at
monthly visits during the first six months after ART initiation.
Subsequently, visits were scheduled less frequently (every 2–3
months) for clinically stable patients. All medical care was
provided by physicians, supported by a team of nurses and
adherence counsellors. At every clinical encounter, key issues were
systematically addressed, including the clinical evolution, evalua-
tion of treatment response and ART-related toxicity. Adherence
was evaluated by pill counts at every visit, and using the visual
analogue scale (VAS) every six months. Baseline laboratory testing
included haematology, liver function tests, hepatitis B/C serology
and CD4 cell count determination (FACSCount (Becton Dick-
inson). After ART initiation, a full blood count and CD4 cell count
was done every six months. During the first months of ART, liver
function tests were performed more regularly. In case of suspicion
of treatment failure, a viral load test was done. Clinical and
immunological criteria were used to guide indications for viral
load testing. Cotrimoxazole prophylactic treatment was given for
all WHO stage II/III/IV patients and all those with a CD4 count
,200 cells/mL. All patients with WHO stage 4 disease or a CD4
count ,100 cells/mL were started on fluconazole primary
prophylaxis. Patients not presenting at their scheduled visit were
contacted by phone. Those living in the neighbourhood of the
hospital were visited at home. Patients not presenting at the
hospital for a period of 6 months without additional information
were defined lost to follow-up (LTFU). Additional program details
and outcome data of the antiretroviral treatment program in
SHCH have been published before [10,11].
Outcome measures
All patients on D4T-containing regimens were routinely
screened for associated toxicity using a standardized approach.
At every clinic visit, patients were assessed for symptoms suggestive
of symptomatic hyperlactatemia or lactic acidosis. Lactate level
was measured for suspected cases only. Since no pH determination
could be done, cases of symptomatic hyperlactatemia (SH) and
lactic acidosis (LA) could not be differentiated and were grouped
together as SH/LA. A case of SH/LA was defined as a patient on
ART, presenting with compatible symptoms with other mimicking
conditions ruled out, and a lactate level $2.5 mmol/L (capillary
blood, Accutrend Lactate). D4T was systematically replaced for
these patients. Up to 2005, no lactic acid levels could be measured
and diagnosis was clinical. Neuropathy was assessed clinically by
the HIV physician, D4T was substituted in case of WHO grade
III/IV severity. Patients were assessed for lipoatrophy (loss of
subcutaneous fat in the face, arms, legs, cheeks, buttocks) at every
encounter by self-report and clinical assessment. Decisions to
substitute D4T were guided by the clinical severity of lipoatrophy
combined with the patient’s preference and perception of the body
changes. Consequently, stavudine was essentially replaced for
reasons of lipoatrophy if 1) clinically severe or 2) patients perceived
this as severe and disturbing, even though clinically it was defined
as less pronounced.
Data collection and statistical analysis
Clinical and laboratory data were prospectively collected on a
daily basis, using standardized data collection tools and stored in a
database. Quality control of the stored data was done at regular
intervals.
The primary outcome was time to D4T substitution due to
suspected D4T toxicity. We will refer to this in the text as
treatment-limiting (or severe) D4T toxicity. The cumulative
incidence of D4T substitution due to suspected toxicity was
calculated using the Kaplan Meier methodology. Patients were
censored at the date of D4T substitution, at the last visit for
patients that died, were transferred out or were lost to follow-up,
and at December 31, 2010 for the remainder. Patients switched to
non-D4T containing second line regimens due to virological
failure were censored at the date of switching and defined as
having experienced no D4T-related toxicity event. A risk factor
analysis was performed using multivariate Cox regression.
Collinearity between variables was assessed. We used a back-
ward selection method, retaining those variables with P-
values,0.05 in the final model. Data analysis was done using
STATA version 11. The level of significance was set at P,0.05.
Ethical issues
Since the launch of the HIV care program, clinical data have
been routinely collected for purposes of program monitoring and
evaluation, and research activities. Patients were requested to give
written informed consent to store and use the data. No linkage of
these data with other sources was done. The data collection and
informed consent procedure were approved by the Institutional
Review Board ITM (Institute of Tropical Medicine, Antwerp) and
the Institutional Review Board SHCH (Sihanouk Hospital Center
of HOPE). No patient identifiers were included in the dataset used
for this analysis.
Results
Characteristics of the study population
By December 2010, 2581 adult patients on D4T-containing
regimen were included in analysis, with a median follow-up time of
1.3 years. Of these, 1341 (52%) were female, the median age at the
start of treatment was 35 years. Eighty percent were in WHO
stage III/IV at treatment initiation. The median baseline CD4
count was 87 cells/mL. The most frequent ART regimen was
D4T/lamivudine/nevirapine, with 72% of patients initiating this
D4T Drug Toxicity
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at ART initiation (Table 1).
Incidence and timing of D4T-related toxicity
Out of 2581 adult patients initiating a D4T-containing regimen,
D4T was replaced in 276 (10.7%) patients for suspected D4T-
related neuropathy, 14 (0.5%) for SH/LA and 957 (37.1%) for
lipodystrophy. All reported cases of SH/LH were confirmed by
lactic acid determination. The main early side effect was peri-
pheral neuropathy (7.0% by 1 year), with a cumulative incidence
of 16.6% and 19.0% by 3 and 6 years respectively. SH/LA was
mainly seen after the first six months but remained rare overall,
with a cumulative incidence of 1% by 6 years. After the first year,
lipoatrophy became the predominant side effect, with a cumulative
incidence of 56.1% and 72.4% by 3 and 6 years respectively
(Table 2; Figure 1).
Risk factors for D4T-related toxicity
In univariate analysis, older age (.40 years), low baseline body
mass index (BMI) (,18.5 kg/m
2), and low baseline haemoglobin
(,10 g/dL) were associated with increased risk of D4T-associated
neuropathy (Table 3). Higher baseline BMI (.25 kg/m
2), use of
efavirenz and being on TB treatment at ART initiation were
associated with increased risk of SH/LA. Lipoatrophy was
positively associated with older age and female sex. An increased
risk was observed with low baseline CD4 cell count (,200 cells/
mL) and low baseline haemoglobin. In multivariate analysis,
neuropathy remained associated with older age and low baseline
haemoglobin. Being female, overweight (BMI.25 kg/m
2), and on
TB treatment at ART initiation increased the likelihood of SH/
LA. Lipoatrophy was positively associated with female gender and
older age. A reduced risk was seen for patients initiating ART with
a baseline CD4 count .200 cells/mL (Table 3).
Discussion
This paper is the first to provide estimates of long-term toxicity
related to D4T up to six years after treatment initiation from
LMICs. By six years on D4T, lipoatrophy was the predominant
side-effect, requiring treatment substitution in seven out of ten
patients. For each of the different D4T-toxicities, distinct risk
factors were identified, indicating which patients might require
more close toxicity-monitoring, should avoid D4T altogether or
should be prioritized for phasing-out of D4T.
Our findings of older age and female sex as risk factors for
lipoatrophy are consistent with other reports from LMIC [12,13].
Regarding baseline CD4 cell count, conflicting data have been
reported [12,13]. Our data confirm the reported association of
older age and neuropathy [12,14,15]. Whereas most previous
studies have reported advanced HIV stage as a risk factor for
neuropathy, we observed an increased risk associated with low
baseline haemoglobin. Possibly, this is merely a reflection of
advanced disease at ART initiation [10,13]. Alternatively, recent
studies have observed the strong and independent prognostic
information contained in both baseline and time-updated
haemoglobin levels, even after adjustment for CD4 cell count
Table 1. Baseline characteristics of adult patients initiating
stavudine-containing antiretroviral treatment (N=2581).
Age (years) - median (IQR) 35 (30–40)
Sex - n (%)
Male 1240 (48)
Female 1341 (52)
Baseline WHO clinical stage - n (%)
Stage I 127 (4.9)
Stage II 404 (15.7)
Stage III 1081 (41.9)
Stage IV 969 (37.5)
Baseline body weight (kg) – median (IQR) 49 (43–55)
Baseline body mass index (kg/m
2) - median (IQR) 19 (17–21)
Baseline CD4 count (cells/mL) - median (IQR) 87 (25–206)
Baseline haemoglobin (g/dL) - median (IQR) 11.3 (9.9–12.6)
Treatment regimen - n (%)
Stavudine/lamivudine/nevirapine
a 1869 (72.5
Stavudine/lamivudine/efavirenz
a 719 (27.5)
On tuberculosis treatment at ART initiation - n (%) 686 (26.6
Follow-up time with exposure to D4T (years) - median (IQR) 1.3 (0.8–2.3)
IQR: interquartile range, WHO: world health organization, ART: antiretroviral
therapy.
aFrom 2006, stavudine was prescribed as 30 mg bid, irrespective of body
weight. Prior to that, 40 mg bid was given for individuals with a body weight
.60 kg.
doi:10.1371/journal.pone.0030647.t001
Figure 1. Cumulative incidence of lipoatrophy. Kaplan-Meier
curve showing the proportion of patients substituting stavudine due to
lipoatrophy.
doi:10.1371/journal.pone.0030647.g001
Table 2. Incidence of severe toxicity related to stavudine
(N=2581).
Stavudine-
related toxicity
Events
(%)
Rate/
1000 py
Cumulative incidence (%)
– Kaplan-Meier estimates
a
6 m 12 m 36 m 60 m
Neuropathy 276 (10.7) 63.8 2.1 7.0 16.6 19.0
Lactic acidosis 14 (0.5) 3.2 0.1 0.6 0.7 1.0
Lipoatrophy 957 (37.1) 221.1 0.8 7.0 56.1 72.4
aKaplan-Meier estimates: time to first severe toxicity (ie requiring treatment
change) at specified months on ART; py:: patient years.
doi:10.1371/journal.pone.0030647.t002
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did not find an association of neuropathy with TB treatment.
Possible reasons for this could include differences in analytical
approach, management of toxicity or timing of ART initiation for
patients on TB treatment.
With regards to SH/LA, the association with the use of
tuberculosis treatment is somehow surprising and has not been
reported yet. In one case-control study, efavirenz was identified as
a risk factor for lactic acidosis [18]. Whether this could be the
mechanism behind our observed association with tuberculosis
treatment, albeit not identified in multivariate analysis, remains to
be determined. Alternatively, rapid weight gain after ART
initiation, identified as a risk factor for lactic acidosis in a South
African study, might be implicated for patients on tuberculosis
treatment [12]. Finally, it needs to be pointed out that TB
treatment and the use of EFV are closely related variables.
Although no clear problem of collinearity was detected during
analysis, the problem cannot be entirely ruled out.
Cost has been a major reason for the ongoing use of D4T-
containing ART in LMIC. Despite recent cost reductions,
tenofovir-based regimens are still more than twice as expensive
in terms of drug costs. In Cambodia, the low cost of D4T is a key
argument for maintaining this drug within first line treatment
regimens for the next years to come. Our data suggest that the
cost-saving effect with D4T-use is limited in time, given the high
long-term rates of D4T-replacement. Moreover, its ongoing use
continues to expose patients to drug toxicity, with all its negative
implications. Whereas our data reinforce the need to phase-out
D4T to better tolerated regimens in LMIC, it is clear that this is
a major operational undertaking that should be implemented in a
phased and controlled manner. In this regard, our experience
could be of interest for national programs willing to implement a
gradual phasing-out of D4T. By combining patient education,
close monitoring for D4T-toxicities, integrating the patient’s
perception and applying a low threshold for D4T-replacement, a
gradual phasing-out of D4T can be expected. Additionally, the
occurrence of toxicity could be significantly reduced by
prioritizing those at highest risk of D4T toxicity, based on the
risk factors identified. Importantly, patient support relative to a
uniform and quick D4T replacement strategy might be enhanced
with this more targeted approach. A recent study from
Cambodia on systematic substitution of zidovudine for D4T
highlighted that a fraction of patients preferred to remain on
D4T-based HAART [19]. Imposing a treatment change without
patient approval might negatively affect on the adherence to the
new regimen.
Table 3. Risk factors for severe toxicity related to stavudine.
Risk factors Neuropathy Lactic acidosis Lipoatrophy
HR (95% CI) aHR (95% CI) HR (95% CI) aHR (95% CI) HR (95% CI) aHR (95% CI)
Sex
Male 1 1 1 1 1
Female 1.1 (0.9–1.4) 2.5 (0.8–8.1) 3.8 (1.1–12.5) 2.2 (1.9–2.5) 2.3 (2.0–2.6)
Age
#4 0 y e a r s 111 11
.40 years 1.9 (1.5–2.4) 1.8 (1.4–2.3) 2.8 (1.0–8.1) 1.1 (1.0–1.3) 1.3 (1.1–1.4)
Baseline WHO clinical stage
I/II 1 1 1
III/IV 1.4 (1.0–2.0) 1.5 (0.3–6.7) 1.0 (0.9–1.2)
Baseline BMI
#25 kg/m
2 -1 1 1
.25 kg/m
2 - 6.4 (2.0–20.5) 12.6 (3.7–43.1) 0.9 (0.7–1.3)
$18.5 kg/m
2 1- - - -
,18.5 kg/m
2 1.3 (1.0–1.7) - - - -
Baseline CD4 count
$200 cells/mL1 1 11
,200 cells/mL 1.1 (0.8–1.5) 0.8 (0.3–2.6) 1.2 (1.0–1.4) 1.3 (1.1–1.5)
Baseline haemoglobin
$10 g/dL 1 1 1 1
,10 g/dL 1.7 (1.4–2.2) 1.7 (1.4–2.2) 1.3 (0.4–4.3) 1.2 (1.0–1.3)
NNRTI at start
EFV 1 1 1
NVP 0.9 (0.7–1.1) 0.3 (0.1–0.7) 0.9 (0.8–1.1)
On TB treatment at ART start
No 1 1 1 1
Yes 1.1 (0.9–1.5) 5.4 (1.8–16.0) 8.6 (2.7–27.5) 1.0 (0.9–1.2)
aHR: adjusted hazard ratio, CI: confidence interval, WHO: world health organization, BMI: body mass index, NNRTI: non-nucleoside reverse transcriptase inhibitor; EFV:
efavirenz; NVP: nevirapine; TB: tuberculosis; ART: antiretroviral treatment.
doi:10.1371/journal.pone.0030647.t003
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years after ART initiation [12,15]. Although incidence of
neuropathy in our study was lower, our three-year estimates on
lipoatrophy are around twice those recently reported in an African
cohort [15]. This could in part relate to the strict criteria for D4T-
substitution in this program, relying on a scoring-system of clinical
severity of changes in different body sites. In contrast, we also
considered the patient’s perception and preference. Indeed, recent
evidence is consistently pointing out that the subjective experience
of ART-related toxicities might be as an important parameter to
monitor in ART programs besides the ‘objective’ changes [20–23].
Self-reported physical and psychological symptoms were identified
as strong and independent risk factors for subsequent treatment
failure in a recent study [24]. From an operational perspective, the
patient’s perception is probably an integral part in quantifying the
(‘subjective’) severity of toxicities. Integrating this in therapeutic
decisions could contribute towards greater adherence to proposed
interventions and towards improvement in the quality of life. This
might be especially true for toxicities like body changes, where
clear inter-individual differences in perception could exist. The
negative impact of perception of body changes on quality of life
and adherence has been reported in a number of studies [25–28].
A number of limitations have to be mentioned. This is a
retrospective analysis, using data from a treatment program
setting. Data on D4T dosing were not recorded in the database.
However, given the overall low body weight in this population, few
patients initiated high dose D4T (40 mg bid) before revision of the
guidelines in 2006. D4T drug changes were driven by suspicion of
D4T toxicity by the clinician, hence not necessarily with formal
proof of D4T as the culprit drug. Reported data merely
demonstrate associations, and not causation. Moreover, this
program was probably better resourced with more intensive
monitoring compared to other field settings, and this could
possibly have resulted in over diagnosis of toxicities. With
increasing experience of the program, diagnosis may have been
influenced by negative perceptions about D4T by physicians and
patients. However, patients were systematically evaluated at each
clinical visit, with standard clinical assessment, patient manage-
ment and reporting. We also note that data were collected
prospectively using standardized data collection tools, with
continuous monitoring of data quality and clinical management
practices. Still, it remains that the unavailability of technical
investigations to more rigorously diagnose the different toxicities
could have led to misclassification. Moreover, at the start of the
program, no lactic acid determination could be done. For
lipoatrophy, diagnostic tools such as DEXA-scanning might have
allowed to define the exact incidence of lipoatrophy over time.
However, our main research question was not to define what
happens ‘biologically’, but rather ‘operationally’ ie to what extent
and for what reasons D4T is replaced over time within a program
with close toxicity monitoring.
D4T-based treatment regimens in low-income countries are
associated with significant long-term toxicities. With seven out of
ten patients developing lipoatrophy by six years of treatment,
lipoatrophy represents the major long-term side-effect. Until D4T
has been phased-out completely, close monitoring for toxicity
combined with the integration of the patient’s perspective and a
low threshold for D4T-replacement is recommended.
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